Mangoceuticals, Inc. (MGRX)
NASDAQ: MGRX · Real-Time Price · USD
0.2251
-0.0067 (-2.89%)
Oct 26, 2026, 10:01 AM EDT - Market open
Mangoceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.32 | 0.46 | 0.62 | 0.73 | 0.01 | - | |
Revenue Growth | -38.91% | -25.96% | -15.81% | 8083.16% | - | - |
Cost of Revenue | 0.14 | 0.21 | 0.24 | 0.3 | 0 | - |
Gross Profit | 0.17 | 0.25 | 0.38 | 0.43 | 0 | - |
Selling, General & Admin | 3.84 | 5.93 | 5.54 | 6.39 | 2 | 0.07 |
Amortization of Goodwill & Intangibles | 1.12 | 1.12 | 0.72 | - | - | - |
Operating Expenses | 13.33 | 17.84 | 8.62 | 8.55 | 2 | 0.07 |
Operating Income | -13.16 | -17.59 | -8.24 | -8.12 | -1.99 | -0.07 |
Interest Expense | -0.65 | -0.1 | -0.01 | - | -0.01 | -0 |
Interest & Investment Income | - | - | - | 0.01 | - | - |
Other Non Operating Income (Expenses) | -0.04 | -1.56 | -0.45 | -1.1 | - | - |
EBT Excluding Unusual Items | -13.84 | -19.26 | -8.71 | -9.21 | -2 | -0.07 |
Asset Writedown | -1.24 | -1.24 | - | - | - | - |
Legal Settlements | 0 | -0.13 | - | - | - | - |
Other Unusual Items | -0.02 | -0.02 | - | - | - | - |
Pretax Income | -15.1 | -20.64 | -8.71 | -9.21 | -2 | -0.07 |
Earnings From Continuing Operations | -15.1 | -20.64 | -8.71 | -9.21 | -2 | -0.07 |
Minority Interest in Earnings | 0 | 0 | 0 | - | - | - |
Net Income | -15.1 | -20.64 | -8.71 | -9.21 | -2 | -0.07 |
Preferred Dividends & Other Adjustments | 1.18 | 1.18 | 0.8 | - | - | - |
Net Income to Common | -16.28 | -21.82 | -9.51 | -9.21 | -2 | -0.07 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 15 | 10 | 2 | 1 | 1 | 1 |
Shares Outstanding (Diluted) | 15 | 10 | 2 | 1 | 1 | 1 |
Shares Change | 208.91% | 408.93% | 84.23% | 49.22% | 34.98% | - |
EPS (Basic) | -1.10 | -2.17 | -4.80 | -8.58 | -2.78 | - |
EPS (Diluted) | -1.10 | -2.17 | -4.80 | -8.58 | -2.78 | - |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -3.89 | -5.85 | -4.86 | -7 | -1.39 | -0.07 |
Free Cash Flow Per Share | -0.26 | -0.58 | -2.46 | -6.52 | -1.93 | -0.13 |
Gross Margin | 54.43% | 54.91% | 61.70% | 58.99% | 54.26% | - |
Operating Margin | -4173.65% | -3858.11% | -1337.90% | -1109.84% | -22279.70% | - |
Profit Margin | -5164.40% | -4784.65% | -1543.87% | -1259.40% | -22352.11% | - |
Free Cash Flow Margin | -1234.31% | -1282.89% | -789.74% | -957.07% | -15545.59% | - |
EBITDA | -12.1 | -15.87 | -7.51 | -8.09 | -1.99 | - |
D&A For EBITDA | 1.06 | 1.72 | 0.73 | 0.02 | 0 | - |
EBIT | -13.16 | -17.59 | -8.24 | -8.12 | -1.99 | -0.07 |